Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-20
2009-02-10
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07488711
ABSTRACT:
Methods for inhibiting endothelial cell growth and angiogenesis, and suppressing tumor growth using calreticulin, fragments of calreticulin and variants of calreticulin are provided. Such methods are useful for the treatment of cancer and diseases associated with unwanted angiogenesis, for example chronic retinal detachment.
REFERENCES:
patent: 5426097 (1995-06-01), Stern et al.
patent: 5591716 (1997-01-01), Siebert et al.
patent: 6596690 (2003-07-01), Tosato et al.
patent: 2140814 (1996-07-01), None
patent: WO 89/09273 (1989-10-01), None
patent: WO 95/13828 (1995-05-01), None
patent: WO 96/23001 (1996-08-01), None
patent: WO 96/36643 (1996-11-01), None
patent: WO 00/50080 (2000-08-01), None
Angiolillo et al.,Leuk Lymphoma19(3-4):267-276, 1995.
Araya et al.,Eur Cytokine Netw. 14:128-33, 2003, abstract only.
Dai et al.,Arteriosclerosis, Thrombosis and Vascular Biology, 17(11):2359-2368, 1997 (abstract only); Medline abstract No. 1998073667, XP002133012.
Dedhar,TIBS, 19:269-271, 1994.
Kishore et al.,Biochem. J., 322(2):543-550, 1997 (abstract only); Medline abstract No. 97218114, XP002133013.
Kuwabara et al.,J. Bio. Chem., 270(14):8179-8187, 1995.
Kwon et al.,Mol. Biol. of the Cell, 11:1433-1443, 2000.
McDonnell et al.,J. Bio. Chem., 271(14):7891-7894, 1996.
Michalak et al.,Biochem. J., 285:681-692, 1992.
Nash et al.,Mol. &Cell. Biochem., 135:71-78, 1994.
Pike et al.,Chemical Abstracts, 130(14), abstract No. 177891, 1999; &J. Experimental Medicine, 188(12):2349-2356, 1998.
Pike et al.,Blood, 94(7):2461-2468, 1999.
Rokeach et al.,Protein Engineering, 4(8):981-987, 1997.
Routsias et al.,Clinical and Experimental Immunology, 91(3):437-441, 1993 (abstract only); Medline abstract No. 93185299, XP002133014.
Sontheimer et al.,J. Invest. Med.,43(4):362-370, 1995.
Stuart et al.,Febs Letters, 397:245-249, 1996.
Tosato et al., “Calreticulin and Tumor Suppression,” Chapter 16 inCalreticulin, 2nd ed., edited by Eggleron et al., Plenum Publishing, p. 162-179, 2003.
Pike Sandra E.
Tosato Giovanna
Yao Lei
Klarquist & Sparkman, LLP
The United States of America as represented by the Secretary of
Yu Misook
LandOfFree
Use of calreticulin and calreticulin fragments to inhibit... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of calreticulin and calreticulin fragments to inhibit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of calreticulin and calreticulin fragments to inhibit... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4118651